ebola
viru
ebov
infect
caus
lethal
hemorrhag
fever
human
result
mortal
ebov
outbreak
sporad
unpredict
natur
therefor
vaccin
abl
provid
durabl
immun
need
protect
risk
exposur
viru
studi
assess
longterm
efficaci
vesicular
stomat
viru
vsv
base
vaccin
vsv
gebovgp
two
rodent
model
ebov
infect
mice
guinea
pig
first
immun
plaqu
form
unit
pfu
vsv
gebovgp
respect
challeng
mice
lethal
dose
mouseadapt
ebov
maebov
month
vaccin
provid
complet
protect
survivor
protect
month
vaccin
challeng
guinea
pig
lethal
dose
guinea
pigadapt
ebov
gaebov
month
vaccin
result
survivor
month
vaccin
surviv
month
vaccin
weight
loss
clinic
sign
observ
surviv
anim
antibodi
respons
analyz
use
sera
individu
rodent
level
ebov
glycoproteinspecif
igg
antibodi
measur
immedi
challeng
appear
correl
protect
studi
confirm
vaccin
vsv
gebovgp
abl
confer
longterm
protect
ebola
infect
mice
guinea
pig
support
followup
studi
nonhuman
primat
crown
ebola
viru
ebov
infect
caus
sever
diseas
character
hemorrhag
multiorgan
failur
death
untreat
human
case
past
ebov
outbreak
sporad
natur
confin
central
africa
aggreg
number
infect
earli
caus
death
total
case
case
fatal
rate
ebov
outbreak
west
african
countri
guinea
liberia
well
confirm
import
case
sierra
leon
sever
suspect
case
surround
countri
indic
ebov
geograph
widespread
previous
thought
ident
ebov
reservoir
remain
elus
despit
effort
although
suggest
fruit
bat
one
potenti
reservoir
speci
complic
strategi
erad
ebov
prevent
transmiss
human
target
reservoir
vaccin
result
need
prevent
vaccin
program
tailor
human
high
risk
exposur
ebov
resid
area
consid
endem
ebov
primari
health
care
provid
endem
area
well
biosafeti
level
bsl
laboratori
research
sever
factor
consid
potenti
implement
ebov
vaccin
program
includ
crossprotect
ebola
speci
preexist
immun
recipi
popul
vaccin
vector
eas
implement
vaccin
regimen
sustain
vaccineinduc
protect
sever
experiment
vaccin
platform
express
ebov
glycoprotein
gp
viral
antigen
choic
immun
demonstr
protect
nonhuman
primat
nhp
lethal
ebov
challeng
vaccin
platform
includ
dna
prime
human
adenoviru
serotyp
boost
alon
viruslik
particl
human
parainfluenza
viru
type
rabi
viru
well
vesicular
stomat
viru
vsv
http
candid
list
liveattenu
vsvbase
vaccin
vsv
gebovgp
uniqu
demonstr
prophylact
postexposur
efficaci
suggest
vaccin
abl
rapidli
establish
protect
immun
recipi
immun
mucos
vaccin
vsv
gebovgp
via
intranas
oral
rout
still
protect
nhp
eas
difficulti
administr
elimin
use
needl
vsvbase
vaccin
express
gp
either
marburg
viru
marv
sudan
viru
sudv
known
vsv
gmarvgp
vsv
sudvgp
respect
abl
protect
homolog
viru
challeng
blend
vaccin
consist
equal
part
vsv
gebovgp
vsv
gmarvgp
vsv
gsudvgp
confer
complet
protect
ebov
marv
sudv
challeng
complet
protect
also
achiev
nhp
challeng
tai
forest
viru
tafv
suggest
evid
crossprotect
vsv
gebovgp
previous
administ
emerg
treatment
research
compassion
ground
suspect
ebov
exposur
laboratori
asid
fever
detect
h
vaccin
recipi
remain
healthi
clinic
trial
need
posit
sign
safeti
vsvbase
vaccin
preexist
immun
vsv
preval
human
therefor
expect
signific
factor
potenti
vaccin
campaign
vsvbase
vaccin
lack
studi
investig
sustain
protect
confer
vsvbase
vaccin
studi
involv
pathogen
protect
observ
month
mice
immun
vsv
encod
sever
acut
respiratori
syndrom
coronaviru
spike
protein
addit
mice
vaccin
recombin
vsv
encod
hemagglutinin
antigen
influenza
viru
still
complet
protect
year
vaccin
vsv
express
and
viru
glycoprotein
still
efficaci
month
syrian
hamster
protect
and
viru
challeng
still
observ
syrian
hamster
year
vsv
immun
howev
possibl
distinguish
vaccin
efficaci
increas
resist
infect
age
control
anim
recent
vsv
gmarvgp
vaccin
shown
provid
full
protect
cynomolgu
macaqu
challeng
month
immun
demonstr
vsv
platform
potenti
provid
durabl
immun
longterm
protect
ebov
infect
yet
publish
experiment
vaccin
list
aim
studi
investig
whether
vsv
gebovgp
administr
provid
longterm
protect
ebov
challeng
mice
guinea
pig
purpos
studi
defin
longterm
extend
beyond
month
vaccin
two
past
studi
demonstr
import
antibodi
respons
vsv
gebovgpmedi
protect
nhp
elev
igg
level
statist
correl
surviv
vsv
gebovgpvaccin
ebovchalleng
nhp
studi
also
test
whether
humor
respons
form
neutral
antibodi
nab
igg
antibodi
indic
sustain
protect
determin
whether
longterm
protect
could
achiev
singl
inject
vsv
gebovgp
mice
vaccin
via
intraperiton
ip
rout
either
plaqu
form
unit
pfu
vsv
gebovgp
n
dmem
n
mock
treatment
initi
immun
group
five
anim
treatment
challeng
ip
ld
mouseadapt
ebov
maebov
month
vaccin
weight
chang
clinic
symptom
monitor
daili
day
surviv
monitor
day
postinfect
dpi
note
larger
number
anim
dmem
vsv
gebovgp
challeng
month
postvaccin
previous
vaccin
unchalleng
mice
hous
contain
unexpectedli
die
due
old
age
decis
made
challeng
remain
mice
longer
interv
immun
challeng
could
reliabl
assess
beyond
month
anim
model
mocktreat
anim
rapidli
lost
weight
maebov
challeng
succumb
diseas
dpi
mean
time
death
mtd
control
mice
day
contrast
mice
immun
vsv
gebovgp
complet
protect
maebov
challeng
month
vaccin
display
observ
weight
loss
fig
challeng
perform
month
vaccin
anim
protect
maebov
survivor
display
weight
loss
wherea
three
nonsurviv
mice
lost
weight
succumb
diseas
mtd
day
fig
f
sinc
past
studi
describ
import
humor
immun
surviv
ebov
infect
antibodi
respons
mock
vsv
gebovgp
vaccin
mice
measur
serum
sampl
obtain
anim
bled
month
vaccin
humor
immun
respons
evalu
level
ebovspecif
neutral
antibodi
nab
gpspecif
igg
antibodi
ebovspecif
nab
detect
vsv
gebovgp
vaccin
mice
measur
month
vaccin
titer
rang
fig
supplementari
data
contrast
high
titer
gpspecif
igg
detect
immun
mice
time
postvaccin
igg
titer
reach
month
postvaccin
two
mice
two
anim
igg
titer
reach
less
mice
twelv
month
vaccin
gpspecif
igg
titer
decreas
mice
one
previous
strong
respond
igg
titer
declin
level
month
low
respond
fig
supplementari
data
three
mice
lower
igg
titer
measur
month
vaccin
ultim
surviv
maebov
challeng
determin
whether
vsv
gebovgp
efficaci
beyond
month
guinea
pig
vaccin
ip
either
pfu
vsv
gebovgp
n
dmem
mock
treatment
n
group
vsv
gebovgp
immun
dmem
treat
anim
challeng
ip
ld
guinea
pigadapt
ebov
gaebov
month
vaccin
weight
chang
clinic
symptom
monitor
daili
day
surviv
monitor
dpi
gaebov
challeng
dmemtreat
anim
rapidli
lost
weight
succumb
diseas
dpi
mtd
day
contrast
protect
observ
guinea
pig
given
vsv
gebovgp
five
six
anim
protect
challeng
month
vaccin
fig
b
nonsurviv
guinea
pig
succumb
diseas
dpi
surprisingli
complet
protect
observ
anim
challeng
month
group
fig
f
without
observ
weight
loss
determin
level
antibodi
respons
vsv
gebovgp
vaccin
guinea
pig
serum
sampl
obtain
individu
anim
bled
month
vaccin
humor
respons
evalu
titer
nab
total
gpspecif
igg
antibodi
ebovspecif
nab
detect
vsv
gebovgp
vaccin
guinea
pig
titer
rang
measur
month
vaccin
sole
nonsurviv
guinea
pig
lower
nab
level
measur
time
challeng
neutral
antibodi
level
appear
reliabl
measur
protect
anim
challeng
month
vaccin
exhibit
similar
level
nab
shortli
challeng
fig
supplemetari
data
gpspecif
igg
detect
immun
guinea
pig
time
point
postvaccin
titer
month
postvaccin
reach
one
guinea
pig
anim
igg
titer
reach
less
guinea
pig
decreas
circul
igg
titer
observ
surviv
guinea
pig
even
month
vaccin
fig
supplementari
data
anim
lowest
level
circul
gpspecif
igg
surviv
gaebov
challeng
month
vaccin
past
effort
ebov
focus
design
efficaci
vaccin
treatment
achiev
shortterm
protect
control
immedi
neg
impact
stem
outbreak
space
limit
high
biocontain
laboratori
prohibit
cost
maintain
nhp
longer
period
time
also
reason
behind
studi
investig
longterm
protect
ebov
vaccin
data
present
studi
show
singl
inject
vsv
gebovgp
provid
durabl
protect
rodent
similar
previou
studi
vsv
gebovgp
viremia
detect
immun
anim
rtqpcr
perform
sera
month
vaccin
data
shown
clinic
sign
immun
highlight
surviv
guinea
pig
challeng
month
immun
vsvbase
vaccin
promis
longterm
vaccin
candid
howev
unknown
whether
steril
immun
observ
anim
ebov
viremia
measur
challeng
specif
igg
respons
decreas
month
vaccin
mice
could
due
old
age
anim
may
indic
need
booster
vaccin
later
life
addit
primeboost
regimen
may
also
necessari
elicit
protect
immun
respons
older
anim
consist
previou
studi
demonstr
import
antibodi
vsvmediat
immun
studi
show
level
circul
ebov
gpspecif
igg
may
also
reliabl
measur
predict
longterm
vsv
gebovgpinduc
protect
standard
elisa
sever
microlit
sera
hindsight
suffici
predict
surviv
outcom
rodent
decreas
level
circul
specif
igg
may
indic
declin
immun
observ
nonsurviv
mice
poor
vaccin
respons
observ
nonsurviv
guinea
pig
followup
studi
necessari
confirm
trend
note
sinc
igg
antibodi
level
decreas
guinea
pig
time
latest
challeng
antibodi
data
suggest
protect
may
possibl
beyond
month
immun
furthermor
studi
warrant
investig
nhp
allow
full
character
immun
respons
possibl
current
experi
either
due
small
blood
volum
individu
mice
lack
avail
reagent
thoroughli
studi
immun
respons
guinea
pig
present
littl
known
natur
immun
respons
requir
longterm
protect
ebov
studi
conduct
character
sustain
immun
respons
nhp
surviv
initi
ebov
infect
help
monoclon
antibodi
treatment
zmab
four
six
anim
protect
subsequ
rechalleng
took
place
week
origin
exposur
comparison
immun
respons
surviv
nonsurviv
anim
show
nonprotect
immun
respons
gener
first
challeng
indic
absenc
memori
secret
ebov
gpspecif
tcell
coupl
lower
igg
level
immun
respons
also
character
human
survivor
sever
outbreak
ebov
infect
analysi
survivor
kikwit
outbreak
show
ebovspecif
igg
antibodi
still
detect
year
onset
symptom
wherea
two
survivor
yambuku
outbreak
persist
igg
respons
sampl
year
infect
survivor
gabon
outbreak
sampl
decreas
level
ebovspecif
igg
observ
surviv
patient
howev
circul
igg
still
readili
detect
sudv
infect
robust
sudvand
gpspecif
igg
respons
detect
survivor
gulu
outbreak
sampl
year
infect
neutral
antibodi
detect
survivor
preval
sudvspecif
igg
antibodi
amongst
survivor
also
found
declin
time
survivor
total
initi
test
posit
sudvspecif
antibodi
origin
outbreak
chang
retest
month
year
summari
specif
igg
respons
detect
human
survivor
ebola
infect
howev
conclus
trend
drawn
base
result
sampl
nonsurvivor
would
avail
direct
comparison
laboratorybas
approach
use
anim
requir
determin
whether
sustain
immun
respons
suffici
protect
diseas
case
potenti
reexposur
result
present
studi
consist
find
human
give
weight
hypothesi
level
total
gpspecif
igg
antibodi
use
predict
protect
ebov
sever
ebov
vaccin
candid
progress
clinic
trial
day
licens
medic
countermeasur
becom
avail
draw
closer
howev
order
mount
effect
immun
campaign
vaccin
must
also
demonstr
sustain
durabl
protect
reason
period
time
therefor
result
particular
relev
constant
risk
ebov
infect
develop
efficaci
vaccin
capabl
sustain
protect
addit
establish
simpl
depend
measur
test
strength
longterm
vaccineinduc
immun
provid
option
control
futur
ebov
outbreak
anim
work
perform
accord
anim
use
document
aud
approv
anim
care
committe
acc
base
canadian
scienc
center
human
anim
health
cschah
accord
guidelin
outlin
canadian
council
anim
care
ccac
infecti
work
perform
facil
nation
microbiolog
laboratori
winnipeg
canada
recombin
vsv
express
ebov
gp
gener
describ
previous
use
infecti
clone
vsv
indiana
serotyp
briefli
open
read
frame
ebov
gp
gener
use
polymeras
chain
reaction
clone
vsv
plasmid
lack
wildtyp
glycoprotein
sequenc
confirm
transfect
cell
use
lipofectamin
invitrogen
accord
manufactur
instruct
rescu
stock
viru
grown
cell
purifi
use
standard
sucros
cushion
gradient
use
anim
femal
balbc
mice
week
old
use
experi
charl
river
mice
immun
via
ip
rout
pfu
vsv
gebovgp
l
dmem
two
site
inject
contain
pfu
control
anim
given
dmem
mock
treatment
femal
hartley
guinea
pig
week
old
also
purchas
experi
charl
river
guinea
pig
immun
ip
pfu
vsv
gebovgp
ml
dmem
two
site
inject
contain
pfu
control
anim
given
dmem
mice
challeng
ip
ld
ebola
viru
maebov
month
vaccin
wherea
guinea
pig
challeng
ip
ld
ebola
viru
gaebov
month
vaccin
serum
harvest
individu
mice
month
immun
well
individu
guinea
pig
month
vaccin
ebov
gpspecif
igg
antibodi
quantifi
elisa
use
histag
recombin
glycoprotein
captur
antigen
high
bind
halfwel
flat
bottom
polystyren
microtit
plate
thermo
scientif
coat
ng
captur
antigen
dilut
pb
incub
overnight
c
plate
wash
pb
block
pb
skim
milk
incub
h
c
sera
dilut
pb
skim
milk
l
ad
triplic
incub
h
c
wash
horseradish
peroxidis
hrp
conjug
goat
antimous
igg
kpl
dilut
pb
skim
milk
ad
h
c
wash
substrat
abt
h
kpl
ad
min
c
read
versamax
micropl
reader
molecular
devic
nm
data
analyz
softmaxpro
softwar
result
data
express
endpoint
dilut
sampl
deem
posit
absorb
greater
five
standard
deviat
prevaccin
control
sampl
anim
titer
plot
use
graphpad
prism
limit
detect
assay
reciproc
dilut
sampl
assay
triplic
averag
titer
report
harvest
serum
sampl
also
assess
abil
neutral
ebovegfp
cell
serum
inactiv
c
min
sampl
initi
dilut
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
fb
dmem
fb
serial
dilut
dmem
fb
mix
transduc
unit
ebov
encod
enhanc
green
fluoresc
protein
egfp
report
gene
ebola
viru
ebovegfp
incub
c
co
min
mixtur
transfer
onto
subconflu
cell
incub
min
c
co
fb
ad
plate
incub
c
co
h
highest
serum
dilut
cell
score
greater
reduct
quantiti
egfp
express
observ
ispot
fluorospot
reader
system
aid
consid
posit
neutral
antibodi
neutral
titer
report
reciproc
dilut
limit
detect
assay
reciproc
dilut
sampl
assay
triplic
averag
titer
report
